Clinical

After the X-Waiver: Ensuring Access and Quality Care for Opioid Addiction Treatment

Tuesday, April 11, 2023

4:15 PM – 5:30 PM

Location: International Ballroom Section E OMNI

Presenter(s)

Yngvild Olsen, MD, MPH

Director
Center for Substance Abuse Treatment, SAMHSA
Rockville, Maryland
Christopher M. Jones, PharmD, DrPH, MPH

Director of the Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration
Member, Rx Drug Abuse & Heroin Summit Advisory Board
Atlanta, Georgia

Moderator(s)

Kelly J. Clark, MD, MBA, DFASAM, DLFAPA

President
Addiction Crisis Solutions
Member, Rx Drug Abuse & Heroin Summit Advisory Board
Louisville, Kentucky

The Fiscal Year 2023 Federal Omnibus Appropriations Act included several components that change the federal landscape for opioid use disorder treatment and prescribing of controlled substances. This session will provide a real-time update on the elimination of the requirement to obtain a waiver (DATA waiver or X-waiver) to prescribe buprenorphine in office-based settings for the treatment of opioid use disorder (i.e., MAT Act), as well as added new educational requirements for all DEA registered providers (i.e., MATE Act). In addition, this session will place the removal of the DATA waiver in the context of other provider, health system, and patient barriers and opportunities to expand access to buprenorphine-based treatment. Finally, the session will include information about resources and actions being taken at the federal level to support treatment expansion.

Learning Objectives:

Describe recent federal legislative changes related to opioid use disorder treatment and controlled substances prescribing
Identify factors at the provider, health system, and patient levels that serve as barriers to accessing buprenorphine-based treatment for opioid use disorder
Identify provider and patient resources from the Substance Abuse and Mental Health Services Administration that can assist in expanding access to treatment
Discuss actions being taken at the federal level to expand access to medications for opioid use disorder